Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India

Nithin Sashidharan, Smita Shenoy, Meena Kumari Kamal Kishore, Harish Thanusubramanian

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Settings and Design: Observational Study conducted in tertiary care centre. Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Statistical Analysis: Primarily Descriptive. Results: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.

Original languageEnglish
Pages (from-to)XC01-XC04
JournalJournal of Clinical and Diagnostic Research
Volume9
Issue number5
DOIs
Publication statusPublished - 01-05-2015

Fingerprint

Thalidomide
Tertiary Healthcare
Multiple Myeloma
Tertiary Care Centers
Dexamethasone
India
Therapeutics
Safety
lenalidomide
Hematologic Neoplasms
Pharmaceutical Preparations
Sample Size
Observational Studies
Statistical methods

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{62eacf5c077744f8ad20172a0992fc49,
title = "Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India",
abstract = "Background: Multiple myeloma accounts for 1{\%} of all neoplastic disorders and 10{\%} of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Settings and Design: Observational Study conducted in tertiary care centre. Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Statistical Analysis: Primarily Descriptive. Results: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.",
author = "Nithin Sashidharan and Smita Shenoy and Kishore, {Meena Kumari Kamal} and Harish Thanusubramanian",
year = "2015",
month = "5",
day = "1",
doi = "10.7860/JCDR/2015/11798.5895",
language = "English",
volume = "9",
pages = "XC01--XC04",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "5",

}

Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India. / Sashidharan, Nithin; Shenoy, Smita; Kishore, Meena Kumari Kamal; Thanusubramanian, Harish.

In: Journal of Clinical and Diagnostic Research, Vol. 9, No. 5, 01.05.2015, p. XC01-XC04.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India

AU - Sashidharan, Nithin

AU - Shenoy, Smita

AU - Kishore, Meena Kumari Kamal

AU - Thanusubramanian, Harish

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Settings and Design: Observational Study conducted in tertiary care centre. Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Statistical Analysis: Primarily Descriptive. Results: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.

AB - Background: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Settings and Design: Observational Study conducted in tertiary care centre. Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Statistical Analysis: Primarily Descriptive. Results: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.

UR - http://www.scopus.com/inward/record.url?scp=84928990164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928990164&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2015/11798.5895

DO - 10.7860/JCDR/2015/11798.5895

M3 - Article

VL - 9

SP - XC01-XC04

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 5

ER -